Results 151 to 160 of about 74,828 (311)

Well-Differentiated, Low-Grade Subcutaneous Liposarcoma With a Fatal Outcome in a Dog. [PDF]

Vet Med Sci
Badial PR, Rocha TASS, Adorno BA, Ferreira HH, Cagnini DQ.   +4 more
europepmc   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Issues in Assigning the T Category in the Staging of Low-Grade Appendiceal Mucinous Neoplasm and High-Grade Appendiceal Mucinous Neoplasm

Archives of Pathology & Laboratory Medicine, 2023
Sarah E, Umetsu, Sanjay, Kakar
openaire   +2 more sources

B7-H3 membranous expression correlates with histological grading in a two-center cohort of 133 pre-treatment bone and soft tissue sarcoma samples. [PDF]

BMC Cancer
Kloker LD, Rottscholl R, Heitmann JS, Bronsert P, Braig D, Benzler K, Zender L, Deinzer CKW.   +7 more
europepmc   +1 more source

A unique presentation of superinfected pseudomyxoma peritonei secondary to a low-grade appendiceal mucinous neoplasm [PDF]

, 2019
Brianne Sullivan, Nathan Bolton, Umut Sarpel, Deepa Magge   +3 more
openalex   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system. [PDF]

Histopathology
Arends MJ, Esposito I, Gill AJ, Hruban RH, Khoury JD, Kojima M, Montgomery EA, Abdulkareem F, Carneiro F, Costamagna G, Lauwers G, Polydorides AD, Rindi G, Rugge M, Schirmacher P, Srivastava A, Yao J, Hodge JC, Kench JG, Rekhi B, Reyes-Múgica M, Sepulveda AR, Shi C, Puspanathan P, Wijesinghe H, Giesen C, Ruiz BII, Lokuhetty D, WCT standing editorial board, Nagtegaal ID.   +29 more
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Ectopic Olfactory Neuroblastoma of the Maxillary Sinus: A Case Report. [PDF]

Clin Case Rep
Jahandideh H, Yadmehr F, Abrishami M.
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source